Show simple item record

dc.contributor.authorReck, M
dc.contributor.authorKerr, KM
dc.contributor.authorGrohe, C
dc.contributor.authorManegold, C
dc.contributor.authorPavlakis, N
dc.contributor.authorPaz-Ares, L
dc.contributor.authorHuber, RM
dc.contributor.authorPopat, S
dc.contributor.authorThatcher, Nick
dc.contributor.authorPark, K
dc.contributor.authorHilberg, F
dc.contributor.authorBarrueco, J
dc.contributor.authorKaiser, R
dc.date.accessioned2019-03-29T14:22:23Z
dc.date.available2019-03-29T14:22:23Z
dc.date.issued2019en
dc.identifier.citationReck M, Kerr KM, Grohe C, Manegold C, Pavlakis N, Paz-Ares L, et al. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? Future Oncol. 2019 Feb 13.en
dc.identifier.pmid30758227en
dc.identifier.doi10.2217/fon-2018-0948en
dc.identifier.urihttp://hdl.handle.net/10541/621621
dc.description.abstractAbstract A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6-9 months of first-line treatment initiation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/fon-2018-0948en
dc.titleDefining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?en
dc.typeArticleen
dc.contributor.departmentDepartment of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germanyen
dc.identifier.journalFuture Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record